GCF miRNA-223 , -214 Levels in Smokers and Nonsmokers Periodontitis Patients

Expression of microRNA-223 and microRNA-214 in Gingival Crevicular Fluid of Smoker and Nonsmoker Periodontitis Patients, an Observational Diagnostic Accuracy Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06064799

Enrollment

Registered

2023-10-03

Start date

2023-01-01

Completion date

2023-06-30

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis, Adult

Keywords

Periodontitis, microRNA, smoking, GCF, biofluids

Brief summary

Objective: Periodontitis is a multifactorial disease that affects a wide range of populations. However, its pathogenesis remains unclear. miRNAs are now considered potential diagnostic markers for many inflammatory diseases. Thus, the aim of this study was to assess the expression of microRNA-223(miRNA-223) and microRNA-214 (miRNA-214) in gingival crevicular fluid (GCF) of smoker and nonsmoker with periodontitis. Materials and Methods: We conducted a prospective study among 42 participants: 14 healthy controls, 14 nonsmoker periodontitis participants, and 14 smoker with periodontitis. Eligibility criteria for inclusion were consecutive adults, aged 20-60 years, with stage III periodontitis grade B/C and no systemic diseases. All consenting participants had gingival crevicular fluid samples collected after diagnosis to assess miRNA-214 and -223 by quantitative real-time polymerase chain reaction assay.

Interventions

DIAGNOSTIC_TESTmiRNA-223 & -214 detection

miRNA-223 & -214 detection in GCF samples by PCR kits

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* both genders * age from 20 to 60 years * no more than 4 teeth lost due to periodontitis * systemically free participants

Exclusion criteria

* Pregnant or lactating female * participants with a history of an inflammatory or immunological disease * history of any current medication

Design outcomes

Primary

Measure	Time frame	Description
assessment of miRNA-223 & -214 levels in GCF samples in all groups	level of miR-223 & -214 are measured at baseline after the completion of all GCF sample collection carried at the day of enrollment of subjects in the investigation after diagnosis confirmation	PCR kits are used for assessment of miRNA-223 & -214 levels in GCF samples in all groups

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026